Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CHRNA7 | P36544 | 11/20 | 0.67 |
| ▸ | DRD4 | P21917 | 4/20 | 0.42 |
| ▸ | SLC6A12 | P48065 | 1/20 | 0.41 |
| ▸ | SLC6A13 | Q9NSD5 | 1/20 | 0.41 |
| ▸ | HTR3E | A5X5Y0 | 3/20 | 0.41 |
| ▸ | HTR3B | O95264 | 3/20 | 0.41 |
| ▸ | HTR3A | P46098 | 3/20 | 0.41 |
| ▸ | HTR3D | Q70Z44 | 3/20 | 0.41 |
| ▸ | HTR3C | Q8WXA8 | 3/20 | 0.41 |
| ▸ | CHRNB4 | P30926 | 2/20 | 0.41 |
| ▸ | CHRNA3 | P32297 | 2/20 | 0.41 |
| ▸ | SMYD3 | Q9H7B4 | 1/20 | 0.41 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.41 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL6392146 | 1.00 | CHRNA7 (0.67) | CHRNA7DRD4SLC6A12SLC6A13HTR3E | |
| SCHEMBL6098251 | 0.86 | CHRNA7 (0.68) | CHRNA7DRD4SLC6A12SLC6A13 | |
| SCHEMBL6098257 | 0.86 | CHRNA7 (0.68) | CHRNA7DRD4SLC6A12SLC6A13 | |
| SCHEMBL6099507 | 0.86 | CHRNA7 (0.76) | CHRNA7DRD4SLC6A12SLC6A13HTR3E | |
| SCHEMBL6099501 | 0.86 | CHRNA7 (0.76) | CHRNA7DRD4SLC6A12SLC6A13HTR3E | |
| SCHEMBL6100991 | 0.84 | CHRNA7 (0.65) | CHRNA7DRD4SLC6A12SLC6A13 | |
| SCHEMBL6396720 | 0.84 | CHRNA7 (0.69) | CHRNA7DRD4SLC6A12SLC6A13HTR3E | |
| SCHEMBL6100994 | 0.84 | CHRNA7 (0.65) | CHRNA7DRD4SLC6A12SLC6A13 | |
| SCHEMBL6396713 | 0.84 | CHRNA7 (0.69) | CHRNA7DRD4SLC6A12SLC6A13HTR3E | |
| SCHEMBL6488622 | 0.83 | CHRNA7 (0.65) | CHRNA7HTR3ASMYD3 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20030176702-A1 | N-(azabicyclo moieties)-substituted hetero-bicyclic aromatic compounds for the treatment of disease | PHARMACIA & UPJOHN COMPANY | 2003-09-18 | — | — | US | claimed |
| US-6849620-B2 | N-(azabicyclo moieties)-substituted hetero-bicyclic aromatic compounds for the treatment of disease | PFIZER INC (US) | 2005-02-01 | — | — | US | disclosed |
| US-20030176702-A1 | N-(azabicyclo moieties)-substituted hetero-bicyclic aromatic compounds for the treatment of disease | PHARMACIA & UPJOHN COMPANY | 2003-09-18 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20030176702-A1 | N-(azabicyclo moieties)-substituted hetero-bicyclic aromatic compounds for the treatment of disease | CYP1B1, ABCB1, NAT1 | CHRNA7 1187/4885DRD4 2082/4885SLC6A12 2378/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.